Patent News
Synthetic Blood International Announces Acceptance of New PFC Patent
Business Wire - August 31, 1998 09:16
KETTERING, Ohio--(BUSINESS WIRE)--Aug. 31, 1998--Synthetic Blood International Inc. (OTCBB:SYBD) announced today that the U.S. Patent office has issued a notice allowing claims by SYBD in a patent application covering the use of various perfluorocarbons as a blood gas exchange media.
The patent is expected to issue soon.
The patent, "Improved Perfluorocarbons for Biological Gas Exchange," covers methods of using SYBD's proprietary perfluorocarbons in blood substitutes and liquid ventilation products. The application also claims the use of dual perfluorocarbons with different boiling points in liquid ventilation to control exhalation and pulmonary persistence.
"The perfluorocarbons in this patent have synergistic properties that we believe have the potential to revolutionize the current practice of liquid ventilation," said Robert Nicora, president. "We're very pleased to see this latest patent issue, protecting the use of our preferred perfluorocarbons and a unique method of performing liquid ventilation."
Nicora declined to reveal further details of the dual perfluorocarbon method and said that further research is necessary. The company currently holds 13 patents covering perfluorocarbons, including patents already issued or licensed, plus applications currently under submission or in preparation.
SYBD is developing Oxycyte(TM), a perfluorocarbon blood substitute emulsion; Fluorovent(TM), a perfluorocarbon liquid ventilation product; and an implanted biosensor for continuous monitoring of blood glucose levels in diabetics.
SYBD is located in Kettering, Ohio, and has West Coast offices and laboratory facilities in Irvine, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD.
CONTACT: Synthetic Blood International Inc.
Joan Mahan, 800/809-6054 |
